P2B001, a novel once-daily combination therapy, uniquely merges extended-release pramipexole and rasagiline in low doses, targeting Parkinson's Disease (PD) with enhanced efficacy and minimized side effects.
The analysis presented by Pharma Two B highlighted P2B001's impressive safety and tolerability profile compared to placebo and commercially available ER-pramipexole (PramiER), alongside its superior efficacy in addressing motor fluctuations.
At the American Academy of Neurology conference 2024, Pharma Two B presented an integrated analysis of Phase II (NCT01968460) and Phase III (NCT03329508) trials showcasing the safety and tolerability profile of P2B001 ...
